{"organizations": [], "uuid": "14c8d277ddc7911ee65e7927d14b637169f61ead", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-richter-q4-net-profit-misses-esmya/brief-richter-q4-net-profit-misses-esmya-sales-beat-forecast-idUSL8N1Q10Y6", "country": "US", "domain_rank": 408, "title": "BRIEF-Richter Q4 net profit misses, Esmya sales beat forecast", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.032, "site_type": "news", "published": "2018-02-12T07:20:00.000+02:00", "replies_count": 0, "uuid": "14c8d277ddc7911ee65e7927d14b637169f61ead"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-richter-q4-net-profit-misses-esmya/brief-richter-q4-net-profit-misses-esmya-sales-beat-forecast-idUSL8N1Q10Y6", "ord_in_thread": 0, "title": "BRIEF-Richter Q4 net profit misses, Esmya sales beat forecast", "locations": [], "entities": {"persons": [{"name": "esmya", "sentiment": "negative"}, {"name": "gergely szakacs", "sentiment": "none"}, {"name": "daniel wallis", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "richter gedeon vegyeszeti gyar nyrt", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt :\n* Q4 NET PROFIT HUF 6.6 BILLION ($25.91 MILLION) VERSUS HUF 9.9 BILLION ANALYST FORECAST IN PORTFOLIO.HU SURVEY\n* Q4 REVENUES HUF 110.2 BILLION VERSUS HUF 108.8 BILLION ANALYST FORECAST\n* FULL-YEAR REVENUES RISE BY 14.8 PCT Y/Y TO EUR 1.44 BLN * FULL-YEAR 2017 OPERATING PROFIT MARGIN 15.5 PERCENT VERSUS 15-16 PERCENT GUIDANCE\n* FULL-YEAR REVENUES FROM UTERINE FIBROID MEDICINE ESMYA EUR 93 MILLION VERSUS EUR 85 MILLION GUIDANCE\n* EUROPEAN MEDICINES AGENCY IMPOSED TEMPORARY RESTRICTIONS ON ESMYA MEDICINE PENDING A CONCLUSION OF ITS REVIEW INTO RISKS\n* RICHTER HAS SAID RESTRICTIONS ON ESMYA WOULD LEAD TO TEMPORARY LOSS OF REVENUE FROM MEDICINE UNTIL EXPECTED FINAL RULING IN MAY\n* RICHTER SHARES FELL 6.6 PCT TO WEAKEST LEVEL SINCE DEC 2016 ON FRIDAY Further company coverage:\n$1 = 254.68 forints Reporting by Gergely Szakacs; Editing by Daniel Wallis\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T07:20:00.000+02:00", "crawled": "2018-02-13T04:41:52.006+02:00", "highlightTitle": ""}